TY - JOUR
T1 - Patient-centred clinical trial design
AU - Tong, Allison
AU - Scholes-Robertson, Nicole
AU - Hawley, Carmel
AU - Viecelli, Andrea K.
AU - Carter, Simon A.
AU - Levin, Adeera
AU - Hemmelgarn, Brenda R.
AU - Harris, Tess
AU - Craig, Jonathan C.
PY - 2022/8
Y1 - 2022/8
N2 - Patient involvement in clinical trial design can facilitate the recruitment and retention of participants as well as potentially increase the uptake of the tested intervention and the impact of the findings on patient outcomes. Despite these benefits, patients still have very limited involvement in designing and conducting trials in nephrology. Many trials do not address research questions and outcomes that are important to patients, including patient-reported outcomes that reflect how patients feel and function. This limitation can undermine the relevance, reliability and value of trial-based evidence for decision-making in clinical practice and health policy. However, efforts to involve patients with kidney disease are increasing across all stages of the trial process from priority setting, to study design (including selection of outcomes and approaches to improve participant recruitment and retention) and dissemination and implementation of the findings. Harnessing the patient voice in designing trials can ensure that efforts and resources are directed towards patient-centred trials that address the needs, concerns and priorities of patients living with kidney disease with the aim of achieving transformative improvements in care and outcomes.
AB - Patient involvement in clinical trial design can facilitate the recruitment and retention of participants as well as potentially increase the uptake of the tested intervention and the impact of the findings on patient outcomes. Despite these benefits, patients still have very limited involvement in designing and conducting trials in nephrology. Many trials do not address research questions and outcomes that are important to patients, including patient-reported outcomes that reflect how patients feel and function. This limitation can undermine the relevance, reliability and value of trial-based evidence for decision-making in clinical practice and health policy. However, efforts to involve patients with kidney disease are increasing across all stages of the trial process from priority setting, to study design (including selection of outcomes and approaches to improve participant recruitment and retention) and dissemination and implementation of the findings. Harnessing the patient voice in designing trials can ensure that efforts and resources are directed towards patient-centred trials that address the needs, concerns and priorities of patients living with kidney disease with the aim of achieving transformative improvements in care and outcomes.
KW - Clinical trial design
KW - Nephrology
KW - Patient-centred clinical trials
UR - http://www.scopus.com/inward/record.url?scp=85131441607&partnerID=8YFLogxK
U2 - 10.1038/s41581-022-00585-w
DO - 10.1038/s41581-022-00585-w
M3 - Review article
C2 - 35668231
AN - SCOPUS:85131441607
SN - 1759-5061
VL - 18
SP - 514
EP - 523
JO - Nature Reviews Nephrology
JF - Nature Reviews Nephrology
IS - 8
ER -